Corpus Intelligence IC Memo — ACADIANA REHABILITATION 2026-04-26 17:22 UTC
IC Memo — ACADIANA REHABILITATION
Investment Committee Memorandum | LA | 40 beds | Grade C | EBITDA uplift $628K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ACADIANA REHABILITATION

CCN 193096 | IBERIA PARISH, LA | 40 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ACADIANA REHABILITATION is a 40-bed suburban community hospital in IBERIA PARISH, LA with $8.4M in net patient revenue and a -7.9% operating margin. The hospital serves a payer mix of 40.6% Medicare, 1.2% Medicaid, and 58.2% commercial.

Thesis: Turnaround. Our ML models identify $628K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -7.9% to -0.4% (+745bps).

Net Revenue HCRIS$8.4M
Current EBITDA COMPUTED$-663K
Operating Margin COMPUTED-7.9%
Occupancy HCRIS43.5%
Revenue / Bed COMPUTED$210K
Net-to-Gross HCRIS39.3%
Distress Probability ML51.8%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
125
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of -7.9% places it below the state median. Among 125 size-comparable peers (20-80 beds), the median margin is -3.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (20-80), prioritizing same-state peers. 125 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ACADIANA REHABILITATION (Target)LA40$8.4M-7.9%
UNIVERSITY HOSPITAL & CLINICSLA52$158.9M-33.4%
SOUTHERN REGIONAL MEDICAL CORPLA64$97.3M-50.0%
NEW ORLEANS EAST HOSPITALLA60$77.6M-29.7%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ABBEVILLE GENERAL HOSPITALLA44$68.5M3.4%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $628K (745bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$177K+210bp18mo
Denial Rate Reduction12.0%6.5%$170K+202bp12mo
Cost to Collect4.5%2.5%$168K+200bp12mo
A/R Days Reduction5200.0%3800.0%$102K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+11bp6mo

5. EBITDA Bridge

Net Collection Rate
$177K
Denial Rate Reduction
$170K
Cost to Collect
$168K
A/R Days Reduction
$102K
Clean Claim Rate
$10K
Total EBITDA Uplift$628K
Current EBITDA$-663K
+ RCM Uplift+$628K
Pro Forma EBITDA$-36K
Current Margin-7.9%
Pro Forma Margin-0.4%
WC Released (1x)$323K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-1.0M$1.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-1.0M$1.8M0.00x-100.0%
Bull Case9.0x11.0x$-918K$3.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-918K$3.5M0.00x-100.0%
Bear Case11.0x10.0x$-1.1M$-906K0.00x-100.0%
Bear (11x exit)11.0x11.0x$-1.1M$-1.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 51.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 125 hospitals with 20-80 beds
  • Same-state prioritization (n=126)
  • Comp margins: P25=-21.3% / P50=-3.5% / P75=4.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.